CME/CE

Use the tool below to view all available Prova Series

Emerging Therapies in IgAN: Who Could Benefit the Most?
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
IgAN SOC: Strengths and Limits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
1.00 program credit
- Dana Rizk, MD
- Suzuki Yusuke, MD, PhD
1.00 program credit
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
0.75 program credits
- Eileen M. O'Reilly, MD
0.75 program credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
0.75 credits 8 episodes
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 credits 8 episodes
RAS Across Tumors: Who to Test When
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CE
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Severity Assessment: Can You Pin the Stage on the Patient?
Severity Assessment: Can You Pin the Stage on the Patient?
MinuteCE®
Severity Assessment: Can You Pin the Stage on the Patient?
1.00 program credit
- Jennifer Geremia, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Case Review: Targets Are Met—Can You Stick the Landing? 
Case Review: Targets Are Met—Can You Stick the Landing? 
MinuteCE®
Case Review: Targets Are Met—Can You Stick the Landing? 
1.00 program credit
- David Rubin, MD
- Jennifer Geremia, PA-C
1.00 program credit
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit

CME/CE

Popular

Title

Share on ReachMD